TKMR News 20.09 09/17/2014 05:49:14 Tekmira Pharmaceuticals Corp

New Post Public Reply Private Reply Replies (0) Message Board

Sep 17, 2014 at 6:49 AM

Tekmira Pharmaceuticals Corp (TKMR) 20.09 $TKMR

Ebola-Stricken Doc Receives Experimental Drug, But Which One?
at The Street - Thu Sep 11, 1:20PM CDT
Twitter abuzz with speculation that Tekmira's experimental Ebola therapy is being used to treat patient.

Trade Ebola Stocks? Sure, But Don't Bet on Big Business Opportunity
at The Street - Wed Sep 10, 8:36AM CDT
The Ebola outbreak in West Africa is a public health emergency which has also captured the attention of U.S. investors (perhaps I should say traders.)

Ebola Outbreak Strikes Africa: How We're Fighting Back
Brian Orelli, The Motley Fool - Motley Fool - Mon Sep 08, 12:37PM CDT
This week, the World Health Organization announced that the Ebola outbreak in West Africa has killed more than 1,900 people. This is the largest Ebola outbreak in history, with more people dying in this outbreak than all the other outbreaks since the...

'Mad Money' Lightning Round: I Still Want to Own Freeport-McMoRan
at The Street - Sat Sep 06, 5:00AM CDT
Cramer likes Take-Two Interactive over Activision Blizzard and if you wanted Tekmira Pharmaceuticals you're too late.

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Sep 05, 6:37PM CDT
Cramer is looking for bargains, and that means he'll be watching Yahoo!, Apple and Restoration Hardware next week.

J&J Ebola Vaccine Gets Funding, Development to Pick Pace - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 2:37PM CDT
Johnson & Johnson (JNJ) announced that its Ebola vaccine development process will be fast-tracked.

Technical Data on Biotech Stocks - ARIAD Pharma, Tekmira Pharma, Arrowhead Research, Celgene, and Amgen
PR Newswire - Thu Sep 04, 7:55AM CDT
On Wednesday, September 03, 2014, the NASDAQ Composite ended at 4,572.57, down 0.56%, the Dow Jones Industrial Average finished the day 0.06% higher at 17,078.28, and the S&P 500 closed at 2,000.72, down 0.08%. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 740.75, up 0.41%, with the index advancing 6.93% in the previous three months. Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Arrowhead Research Corporation (NASDAQ: ARWR), Celgene Corporation (NASDAQ: CELG), and Amgen Inc. (NASDAQ: AMGN). Free research on these five companies can be accessed at:

BioCryst's Ebola Candidate Moving to Efficacy Study Soon - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 2:08PM CDT
BioCryst 's (BCRX) BCX4430 will be evaluated in a non-human primate study shortly.

Glaxo Up on Accelerated Ebola Vaccine Development Process - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 1:50PM CDT
Glaxo's Ebola vaccine development process has been fast-tracked by an international consortium.

Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK
PR Newswire - Tue Sep 02, 8:00AM CDT
Today, Analysts Review released its research reports regarding WellPoint Inc. (NYSE: WLP), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Zoetis Inc. (NYSE: ZTS), Sanofi SA (NYSE: SNY) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6142-100free.

Nasdaq stocks posting largest percentage increases
AP - Fri Aug 29, 12:19PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:

'Fast Money' Recap: When Is the Next Market Correction?
at The Street - Fri Aug 29, 4:00AM CDT
The trading panel discussed when the market will pull back, cyber attacks and the company making Apple's sapphire screens.

Why Tekmira Pharmaceuticals (TKMR) Stock Is Surging Today
at The Street - Thu Aug 28, 10:12AM CDT
Tekmira Pharmaceuticals (TKMR) surged Thursday as takeover talks swirl around the Vancouver-based biotech company.

Why Tekmira Pharmaceuticals (TKMR) Stock Is Gaining Today
at The Street - Thu Aug 21, 9:30AM CDT
Monkeys sickened by Marburg virus, an Ebola relative that kills in the same way and is equally as fatal, survived the disease after being treated with its experimental drug.

Tekmira Pharmaceuticals (TKMR) Is Today's Dead Cat Bounce Stock
at The Street - Thu Aug 21, 8:45AM CDT
Trade-Ideas LLC identified Tekmira Pharmaceuticals (TKMR) as a "dead cat bounce" (down big yesterday but up big today) candidate

The Zacks Analyst Blog Highlights: Johnson & Johnson, Tekmira Pharmaceuticals, GileadSciences, Allergan and Supernus Pharmaceuticals
PR Newswire - Thu Aug 21, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Johnson & Johnson (NYSE:JNJ-Free Report), Tekmira Pharmaceuticals Corp (Nasdaq:TKMR-Free Report), Gilead Sciences Inc. (Nasdaq:GILD-Free Report), Allergan Inc. (NYSE:AGN-Free Report) and Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN-Free Report).

Healthcare Enjoys Growth Trends: 3 Medical Stocks to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 3:27PM CDT
Favorable industry trends in the pharma and bio-tech space makes the healthcare sector a lucrative investment destination.

Tekmira's Lipid Nanoparticle (LNP) Technology Targeting Marburg Virus Highlighted in Scientific Publication
GlobeNewswire - Wed Aug 20, 1:00PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced the publication of data in a peer-reviewed scientific journal which highlights positive results in an animal model of Marburg virus infection enabled by Tekmira's lipid nanoparticle (LNP) technology.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Steel Dynamics Gears Up for Q3 2026 Earnings Update

Steel Dynamics Preps for Key Earnings Report Folks, we're staring down the barrel of another quarterly earnings report from Steel Dynamics, Inc., and you can bet this one is gonna have plenty of eyes glued. October 19th, 2026, that's when they'll peel back the curtain on how they fared in Q3. Now, buckle up, because this isn't just a numbers game—it’s a snapshot of...

Aspen Dental Brings Comprehensive Care to Whiteville

Bringing Dentistry Closer to Home Now, Whiteville's dental game just got a power-up, with Aspen Dental setting up shop in town. This isn't just another practice popping up—it's a full-on dental hub offering everything from regular cleanings to emergency tooth fixes. And let’s face it, this area's diverse population needs it. The Man Behind the Chair Guess who’s at...

PrideStaff: 8 Years Strong on Franchise Times Top 400

Where PrideStaff Stands in the Franchise Landscape Here's something the staffing world can't ignore: PrideStaff nailed it again, landing among the giants on the Franchise Times Top 400 for the eighth straight year. Sitting at number 217, this ain't just a lucky streak—this is a sustained homerun, my friends. Consistency Is Key, And They're Holding It Consider this...

Protecting Your Family on Halloween: Safety Tips

Avoid Turning Halloween Fun Into a Medical Emergency Halloween should be about ghosts and ghouls, not a dreaded detour to the ER. Yet, every year, adults and kids get carried away with costumes, only to find themselves in a real-life horror show courtesy of a slip, a fall, or a carving mishap. The American Academy of Orthopaedic Surgeons (AAOS) is waving the safety flag,...

Teamsters Secure Landmark Deal for SF Parking Workers

Major Win for San Francisco's Parking Professionals Parking lots and garages across San Francisco might not be the first places you’d look for labor triumphs, but that’s exactly what almost 1,000 members of Teamsters Local 665 have achieved. Under a newly ratified four-year master contract, these parking pros snagged one of the richest deals the industry has seen. A...

Raken Debuts Change Orders: A Game-Changer for Builds

Construction Gets a Streamlined Boost with Raken's New Tool In construction, chaos often partners seamlessly with progress. But Raken is stepping in to shake things up a bit. This isn’t just another run-of-the-mill software update; this is Raken flexing its muscles in the construction tech arena. They’ve rolled out Change Orders, enhancing their project management...

Hexaware Teams with Anthropic for Game-Changing AI Move

A Bold AI Partnership on the Horizon Mutual back-slapping or a deal with authentic grit? Hexaware’s latest tango with Anthropic might just be the jolt enterprises need. Announced under the flickering fluorescent lights of Mumbai, London, and Iselin, Hexaware’s multi-year partnership with Anthropic thrusts Claude, their razor-sharp AI, right into the mix of...

Webull Faces Legal Scrutiny Over Chinese Ties

The Unfolding Drama for Webull Shareholders When you see a ticker like NASDAQ:BULL rolling off your tongue these days, it’s not just about stock prices anymore—it's a whole saga wrapped in legal and geopolitical spice. Following the recent uproar from a House China committee report, Webull found itself thrust into the spotlight for all the wrong reasons. That report...

Rutter Mills Secures $13M in Virginia Injury Cases

The Stakes in Virginia When you drop nine successful injury cases on the scales and they tip over $13 million, that's a story worth dissecting. The two top dogs at Rutter Mills certainly know how to make a splash in the legal puddle, don't they? We're talking about attorneys Adam H. Lotkin and Georgina D. Montgomery here, the legal eagles behind these jaw-dropping...

Lupin Secures FDA Nod for Key Injectable Drug

Lupin's FDA Approval: A Strategic Play in Pharmaceuticals Ah, the thrill of a new approval! Lupin Limited has landed U.S. FDA approval for their Phytonadione Injectable Emulsion, marking a significant stride into the lucrative realm of vitamin K treatments. This approval isn't just a feather in Lupin's cap—it's a calculated move to corner a piece of the estimated $52.3...